Phase 1 Trial of the Safety and Immunogenicity of PENNVAX ® -G DNA Prime Administered by Biojector ® 2000 or CELLECTRA ® EP Device with MVA-CMDR Boost von Ake, Julie, Ratto-Kim, Silvia, Schuetz, Alexandra, Wieczorek, Lindsay, Nguay, Viseth, Kibuuka, Hannah, Sawe, Fredrick, Maboko, Leonard, Polonis, Victoria, Weiner, David, DeSouza, Mark, Sekiziyivu, Arthur, Kosgei, Josphat, Missanga, Marco, Kroidl, Arne, Earl, Patricia, Moss, Bernard, Adams, Elizabeth, Martinez, Ana, Rizvi, Farrukh, Khan, Amir, Sardesai, Niranjan, Michael, Nelson, Marovich, Mary, Robb, Merlin

Volltext

OMIP‐046: Characterization of invariant T cell subset activation in humans von Lal, Kerri G., Leeansyah, Edwin, Sandberg, Johan K., Eller, Michael A.

Volltext

OMIP‐027: Functional analysis of human natural killer cells von Costanzo, Margaret C., Creegan, Matthew, Lal, Kerri G., Eller, Michael A.

Volltext

Anogenital HIV RNA in Thai men who have sex with men in Bangkok during acute HIV infection and after randomization to standard vs. intensified antiretroviral regimens von Phanuphak, Nittaya, Teeratakulpisarn, Nipat, Griensven, Frits, Chomchey, Nitiya, Pinyakorn, Suteeraporn, Fletcher, James LK, Trichavaroj, Rapee, Pattanachaiwit, Supanit, Michael, Nelson, Phanuphak, Praphan, Kim, Jerome H, Ananworanich, Jintanat

Volltext